BioCardia (NSDQ:BCDA) initiated its CardiAmp pivotal trial this week to evaluate its cell therapy at 40 clinical sites across the U.S.
The pivotal trial is a part of the company’s efforts for premarket approval, as regulated by the FDA’s Center for Biologics Evaluation and Research division.
Get the full story at our sister site, Drug Delivery Business News.
The post BioCardia launches pivotal trial for CardiAmp heart failure treatment appeared first on MassDevice.
from MassDevice http://ift.tt/2iMw73Q
Cap comentari:
Publica un comentari a l'entrada